FGFR2 Point Mutations in 466 Endometrioid Endometrial Tumors: Relationship with MSI, KRAS, PIK3CA, CTNNB1 Mutations and Clinicopathological Features

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2012 Mar 3

PMID 22383975

Citations 77

Authors

Sara A Byron

Michael Gartside

Matthew A Powell

Candice L Wellens

Feng Gao

David G Mutch

Paul J Goodfellow

Pamela M Pollock

Affiliations

Soon will be listed here.

Abstract

Mutations in multiple oncogenes including KRAS, CTNNB1, PIK3CA and FGFR2 have been identified in endometrial cancer. The aim of this study was to provide insight into the clinicopathological features associated with patterns of mutation in these genes, a necessary step in planning targeted therapies for endometrial cancer. 466 endometrioid endometrial tumors were tested for mutations in FGFR2, KRAS, CTNNB1, and PIK3CA. The relationships between mutation status, tumor microsatellite instability (MSI) and clinicopathological features including overall survival (OS) and disease-free survival (DFS) were evaluated using Kaplan-Meier survival analysis and Cox proportional hazard models. Mutations were identified in FGFR2 (48/466); KRAS (87/464); CTNNB1 (88/454) and PIK3CA (104/464). KRAS and FGFR2 mutations were significantly more common, and CTNNB1 mutations less common, in MSI positive tumors. KRAS and FGFR2 occurred in a near mutually exclusive pattern (p = 0.05) and, surprisingly, mutations in KRAS and CTNNB1 also occurred in a near mutually exclusive pattern (p = 0.0002). Multivariate analysis revealed that mutation in KRAS and FGFR2 showed a trend (p = 0.06) towards longer and shorter DFS, respectively. In the 386 patients with early stage disease (stage I and II), FGFR2 mutation was significantly associated with shorter DFS (HR = 3.24; 95% confidence interval, CI, 1.35-7.77; p = 0.008) and OS (HR = 2.00; 95% CI 1.09-3.65; p = 0.025) and KRAS was associated with longer DFS (HR = 0.23; 95% CI 0.05-0.97; p = 0.045). In conclusion, although KRAS and FGFR2 mutations share similar activation of the MAPK pathway, our data suggest very different roles in tumor biology. This has implications for the implementation of anti-FGFR or anti-MEK biologic therapies.

Citing Articles

The PIK3CA gene and its pivotal role in tumor tropism of triple-negative breast cancer.

Mallick S, Duttaroy A, Dutta S Transl Oncol. 2024; 50:102140.

PMID: 39369580 PMC: 11491976. DOI: 10.1016/j.tranon.2024.102140.

Landscape of Endometrial Cancer: Molecular Mechanisms, Biomarkers, and Target Therapy.

Bostan I, Mihaila M, Roman V, Radu N, Neagu M, Bostan M Cancers (Basel). 2024; 16(11).

PMID: 38893147 PMC: 11171255. DOI: 10.3390/cancers16112027.

Role of INPP4B in the proliferation, migration, invasion, and survival of human endometrial cancer cells.

Zhao J, Du X, Si W, Zhao X, Zhou Z Histol Histopathol. 2024; 39(9):1197-1208.

PMID: 38318760 DOI: 10.14670/HH-18-711.

Endometrial cancer PDX-derived organoids (PDXOs) and PDXs with FGFR2c isoform expression are sensitive to FGFR inhibition.

Sengal A, Bonazzi V, Smith D, Moiola C, Lourie R, Rogers R NPJ Precis Oncol. 2023; 7(1):127.

PMID: 38062117 PMC: 10703877. DOI: 10.1038/s41698-023-00478-6.

Efficacy of futibatinib, an irreversible fibroblast growth factor receptor inhibitor, in FGFR-altered breast cancer.

Saridogan T, Akcakanat A, Zhao M, Evans K, Yuca E, Scott S Sci Rep. 2023; 13(1):20223.

PMID: 37980453 PMC: 10657448. DOI: 10.1038/s41598-023-46586-y.

References

Davies H, Hunter C, Smith R, Stephens P, Greenman C, Bignell G . Somatic mutations of the protein kinase gene family in human lung cancer. Cancer Res. 2005; 65(17):7591-5. DOI: 10.1158/0008-5472.CAN-05-1855. View

Catasus L, Gallardo A, Cuatrecasas M, Prat J . PIK3CA mutations in the kinase domain (exon 20) of uterine endometrial adenocarcinomas are associated with adverse prognostic parameters. Mod Pathol. 2007; 21(2):131-9. DOI: 10.1038/modpathol.3800992. View

Jang J, Shin K, Park J . Mutations in fibroblast growth factor receptor 2 and fibroblast growth factor receptor 3 genes associated with human gastric and colorectal cancers. Cancer Res. 2001; 61(9):3541-3. View

Cheung L, Hennessy B, Li J, Yu S, Myers A, Djordjevic B . High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability. Cancer Discov. 2011; 1(2):170-85. PMC: 3187555. DOI: 10.1158/2159-8290.CD-11-0039. View

Dutt A, Salvesen H, Chen T, Ramos A, Onofrio R, Hatton C . Drug-sensitive FGFR2 mutations in endometrial carcinoma. Proc Natl Acad Sci U S A. 2008; 105(25):8713-7. PMC: 2438391. DOI: 10.1073/pnas.0803379105. View

Monsonego-Ornan E, Adar R, Feferman T, Segev O, Yayon A . The transmembrane mutation G380R in fibroblast growth factor receptor 3 uncouples ligand-mediated receptor activation from down-regulation. Mol Cell Biol. 1999; 20(2):516-22. PMC: 85119. DOI: 10.1128/MCB.20.2.516-522.2000. View

He L, Hristova K . Pathogenic activation of receptor tyrosine kinases in mammalian membranes. J Mol Biol. 2008; 384(5):1130-42. DOI: 10.1016/j.jmb.2008.10.036. View

Engelsen I, Akslen L, Salvesen H . Biologic markers in endometrial cancer treatment. APMIS. 2009; 117(10):693-707. DOI: 10.1111/j.1600-0463.2009.02467.x. View

Byron S, Gartside M, Wellens C, Mallon M, Keenan J, Powell M . Inhibition of activated fibroblast growth factor receptor 2 in endometrial cancer cells induces cell death despite PTEN abrogation. Cancer Res. 2008; 68(17):6902-7. DOI: 10.1158/0008-5472.CAN-08-0770. View

10.

Jemal A, Siegel R, Xu J, Ward E . Cancer statistics, 2010. CA Cancer J Clin. 2010; 60(5):277-300. DOI: 10.3322/caac.20073. View

11.

Swisher E, Mutch D, Herzog T, Rader J, Elbendary A, Goodfellow P . Differences in patterns of TP53 and KRAS2 mutations in a large series of endometrial carcinomas with or without microsatellite instability. Cancer. 1999; 85(1):119-26. DOI: 10.1002/(sici)1097-0142(19990101)85:1<119::aid-cncr17>3.0.co;2-5. View

12.

Konopka B, Janiec-Jankowska A, Kwiatkowska E, Najmola U, Bidzinski M, Olszewski W . PIK3CA mutations and amplification in endometrioid endometrial carcinomas: relation to other genetic defects and clinicopathologic status of the tumors. Hum Pathol. 2011; 42(11):1710-9. DOI: 10.1016/j.humpath.2010.01.030. View

13.

Barton D, Naik R, Herod J . Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC Trial): a randomized study. Int J Gynecol Cancer. 2009; 19(8):1465. DOI: 10.1111/IGC.0b013e3181b89f95. View

14.

Rudd M, Price J, Fogoros S, Godwin A, Sgroi D, Merino M . A unique spectrum of somatic PIK3CA (p110alpha) mutations within primary endometrial carcinomas. Clin Cancer Res. 2011; 17(6):1331-40. PMC: 3060282. DOI: 10.1158/1078-0432.CCR-10-0540. View

15.

Heiskanen M, Kononen J, Barlund M, Torhorst J, Sauter G, Kallioniemi A . CGH, cDNA and tissue microarray analyses implicate FGFR2 amplification in a small subset of breast tumors. Anal Cell Pathol. 2001; 22(4):229-34. PMC: 4615989. DOI: 10.1155/2001/981218. View

16.

Miller S, Dykes D, Polesky H . A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988; 16(3):1215. PMC: 334765. DOI: 10.1093/nar/16.3.1215. View

17.

Keys H, Roberts J, Brunetto V, Zaino R, Spirtos N, Bloss J . A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2004; 92(3):744-51. DOI: 10.1016/j.ygyno.2003.11.048. View

18.

van Rhijn B, VAN Tilborg A, Lurkin I, Bonaventure J, de Vries A, Thiery J . Novel fibroblast growth factor receptor 3 (FGFR3) mutations in bladder cancer previously identified in non-lethal skeletal disorders. Eur J Hum Genet. 2002; 10(12):819-24. DOI: 10.1038/sj.ejhg.5200883. View

19.

Meyers G, Orlow S, Munro I, Przylepa K, Jabs E . Fibroblast growth factor receptor 3 (FGFR3) transmembrane mutation in Crouzon syndrome with acanthosis nigricans. Nat Genet. 1995; 11(4):462-4. DOI: 10.1038/ng1295-462. View

20.

Zighelboim I, Goodfellow P, Gao F, Gibb R, Powell M, Rader J . Microsatellite instability and epigenetic inactivation of MLH1 and outcome of patients with endometrial carcinomas of the endometrioid type. J Clin Oncol. 2007; 25(15):2042-8. DOI: 10.1200/JCO.2006.08.2107. View